19 October 2026
October BNF + BNFC Knowledge Updates
British National Formulary
This update contains 17 significant changes, 2 new monographs, 2 new preparations and 1 deleted monograph.
Significant changes
Aminophylline: new dose equivalence and conversion statement.
Avacopan: MHRA concludes review of avacopan following reassessment of benefit-risk balance [MHRA/CHM advice].
Avacopan: new important safety information on updated requirements for liver monitoring and stopping rules to mitigate the risk of drug-induced liver injury and vanishing bile duct syndrome.
Cardiovascular disease risk assessment and prevention: updated guidance on secondary prevention.
Dexamethasone with hypromellose, neomycin and polymyxin B sulfate: name change to dexamethasone with neomycin and polymyxin B sulfate.
Diabetes: updated guidance on driving.
Heavy menstrual bleeding: updated guidance on management.
Hypertension: updated guidance on non-drug treatment.
Immune checkpoint inhibitors: updated important safety information on myocarditis-myositis-myasthenia gravis overlap syndrome (advice in avelumab, ipilimumab, nivolumab, pembrolizumab; see example in avelumab).
Influenza vaccine (inactivated): update to guidance for egg allergy.
Influenza vaccine (live): update to guidance for egg allergy and concomitant salicylate use.
Influenza vaccine: updated guidance for 2026/27 influenza season.
Primary biliary cholangitis: updated guidance on the use of seladelpar.
Respiratory syncytial virus immunisation: updated guidance.
Respiratory syncytial virus vaccine (Abrysvo®): new indication and dose for immunisation against respiratory syncytial virus [patients in a clinical risk group; as part of the national immunisation programme].
Type 2 diabetes: updated guidance on management.
Upadacitinib: new indication and dose for giant cell arteritis.
New Monographs
Brinsupri® [brensocatib] for Non-cystic fibrosis bronchiectasis [with two or more exacerbations in the last 12 months].
Tryngolza® [olezarsen] for Familial chylomicronaemia syndrome.
New Preparations
Axhidrox® cream [glycopyrronium bromide] for Severe primary axillary hyperhidrosis.
Enebium® orodispersible tablet [rosuvastatin] for indications relating to hypercholesterolaemia, dyslipidaemia, and prevention of cardiovascular events.
Deleted Monographs
Econazole nitrate.
BNF for Children
This update contains 8 significant changes, 1 dose change, 1 new monograph, 2 new preparations and 1 deleted monograph.
Significant Changes
Aminophylline: new dose equivalence and conversion statement.
Dexamethasone with hypromellose, neomycin and polymyxin B sulfate: name change to dexamethasone with neomycin and polymyxin B sulfate.
Hypertension: updated guidance on non-drug treatment.
Immune checkpoint inhibitors: updated important safety information on myocarditis-myositis-myasthenia gravis overlap syndrome (advice in ipilimumab, nivolumab, pembrolizumab; see example in ipilimumab).
Influenza vaccine (inactivated): update to guidance for egg allergy.
Influenza vaccine (live): update to guidance for egg allergy and concomitant salicylate use.
Influenza vaccine: updated guidance for 2026/27 influenza season.
Respiratory syncytial virus immunisation: updated guidance.
Dose Changes
House-dust mite extracts [update to age range].
New Monographs
Brinsupri® [brensocatib] for Non-cystic fibrosis bronchiectasis [with two or more exacerbations in the last 12 months].
New Preparations
Enebium® orodispersible tablet [rosuvastatin] for Heterozygous familial hypercholesterolaemia (specialist use only); Homozygous familial hypercholesterolaemia (specialist use only).
Itulazax 12 SQ-Bet® [tree pollen extracts] for Moderate-to-severe allergic rhinitis and/or conjunctivitis due to pollen from the birch homologous group [in patients who have failed to respond to anti-allergy drugs] (initiated by a specialist).
Deleted Monographs
Econazole nitrate.
